Journal of Clinical Oncology · 2005 · 178 citations · 15 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyChemotherapy Toxicity ManagementCombination ChemotherapyLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsToxicity ManagementChemotherapy Dose-limiting ToxicityChemotherapy Regimen DesignDose-limiting Toxicity AssessmentNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
PURPOSE: To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non-small-cell lung cancer (NSCLC). In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB/IV NSCLC, performance status (PS) 0 to 2, and adequate organ function were eligible. All patients received paclitaxel 200 mg/m2 plus carboplatin (area under the curve, 6 mg/mL-min) intravenously every 21 days for up to 8 cycles, and were randomly assigned to receive BMS-275291, 1,200 mg orally daily, or placebo until disease progression. The primary study end point was survival (OS); secondary end points included progression-free survival (PFS), response rates (RR), toxicity, and quality of life. RESULTS: From 2000 to 2002, 774 patients were randomly assigned. Pretreatment characteristics were well balanced between arms: median age, 61 years; male sex, 73%; stage IV, 79%; PS 0 to 1, 88%. Interim safety analysis revealed no survival advantage and increased toxicity in the experimental arm, and study treatment was stopped. Median OS, PFS and RR in the final analysis in the BMS-275291 arm were 8.6 months, 4.9 months, and 25.8% respectively, and in the control arm 9.2 months, 5.3 months, 33.7%. Toxicity was significantly higher in the BMS-275291 arm, including flu-like symptoms, rash, hypersensitivity reactions (8.6% v 2.4%), and febrile neutropenia (9.7% v 5.5%). CONCLUSION: BMS-275291 added to chemotherapy increases toxicity and does not improve survival in advanced NSCLC.
15
Estimating the world cancer burden: Globocan 2000
D. Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · International Journal of Cancer · 2001 · 3.7K citations · Full text
Frances A. Shepherd, Janet Dancey, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2000 · 2.2K citations
Medicine, Oncology, Pharmacology +16
Frances A. Shepherd, Giuseppe Giaccone, Lesley Seymour et al. · Journal of Clinical Oncology · 2002 · 258 citations
Medicine, Oncology, Pharmacotherapy +17